Anti-CD79B antibodies and immunoconjugates and methods of use
US9896506B2 · kind B2 · utility
18Cited by
40References
27Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Jun 9, 2015 |
| Grant date | Feb 20, 2018 |
| Priority date | — |
| Expiry date | Jun 9, 2035 |
Classification
- Technology area (CPC Y)Emerging Cross-Sectional Technologies
- CPC primaryY02A50/30
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The present invention is directed to compositions of matter useful for the treatment of hematopoietic tumor in mammals, including immunoconjugates comprising anti-CD79b cysteine-engineered antibody huMA79b.v28, and to methods of using those compositions of matter for the same.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.